Clinical Trial: A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)

U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07805785) titled 'A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)' on Sept. 01.

Brief Summary: The primary objective of this study is to evaluate the effect of 52 weeks of once daily treatment with TPIP compared with placebo on lung function in adults with PPF.

Study Start Date: Dec. 01, 2026

Study Type: INTERVENTIONAL

Condition: Progressive Pulmonary Fibrosis Interstitial Lung Disease

Intervention: DRUG: Treprostinil Palmitil Inhalation Powder

Oral inhalation using a capsule-based dry powder inhaler device.

DRUG: Placebo

Oral inhalation usi...